中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide

文献类型：期刊论文

作者Li, Wenzhuo6,7,8; Zhou, Qingtong5; Cong, Zhaotong5; Yuan, Qingning4; Li, Wenxin5; Zhao, Fenghui7,8; Xu, H. Eric4,6; Zhao, Li-Hua4,6; Yang, Dehua3,6,7,8; Wang, Ming-Wei1,2,3,5
刊名CELL DISCOVERY
出版日期2024-07-17
卷号10期号:1页码:4
DOI10.1038/s41421-024-00700-0
通讯作者Zhao, Li-Hua(zhaolihuawendy@simm.ac.cn) ; Yang, Dehua(dhyang@simm.ac.cn) ; Wang, Ming-Wei(mwwang@simm.ac.cn)
WOS关键词GLUCAGON RECEPTOR AGONIST ; DOUBLE-BLIND ; LY3437943 ; PLACEBO ; PEOPLE
资助项目National Natural Science Foundation of China 82273961 ; Shanghai Institute of Materia Medica, Chinese Academy of Sciences[82273961] ; Shanghai Institute of Materia Medica, Chinese Academy of Sciences[82073904] ; Shanghai Institute of Materia Medica, Chinese Academy of Sciences[81872915] ; Shanghai Institute of Materia Medica, Chinese Academy of Sciences[82273985] ; Shanghai Institute of Materia Medica, Chinese Academy of Sciences[82121005] ; Shanghai Institute of Materia Medica, Chinese Academy of Sciences[81973373] ; Shanghai Institute of Materia Medica, Chinese Academy of Sciences[32200576] ; Shanghai Institute of Materia Medica, Chinese Academy of Sciences[32071203] ; Shanghai Institute of Materia Medica, Chinese Academy of Sciences[82204474] ; National Natural Science Foundation of China[2018ZX09735-001] ; National Natural Science Foundation of China[2018ZX09711002-002-005] ; National Natural Science Foundation of China[2021ZD0203400] ; National Natural Science Foundation of China[2022ZD0213000] ; National Science & Technology Major Project of China - Key New Drug Creation and Manufacturing Program[2022M710806] ; National Science & Technology Major Project of China - Key New Drug Creation and Manufacturing Program[2022M713266] ; Postdoctoral Science Foundation of China[BX20220070] ; Postdoctoral Innovative Talent Support Plan of China[ZDKJ2021028] ; Hainan Provincial Major Science and Technology Project[2023YFA1800804] ; Hainan Provincial Major Science and Technology Project[2022YFC2703105] ; National Key R&D Program of China[XDB37030103] ; CAS Strategic Priority Research Program[2019SHZDZX02] ; Shanghai Municipal Science and Technology Major Project[SKLDR-2023-TT-04] ; State Key Laboratory of Drug Research[21JC1401600] ; Shanghai Municipality Science and Technology Development Fund[23XD1400900] ; Program of Shanghai Academic/Technology Research Leader[22YF1457200] ; Shanghai Sailing Program
WOS研究方向Cell Biology
语种英语
WOS记录号WOS:001271913300001
出版者SPRINGERNATURE
源URL[http://119.78.100.183/handle/2S10ELR8/312392]  
专题新药研究国家重点实验室
通讯作者Zhao, Li-Hua; Yang, Dehua; Wang, Ming-Wei
作者单位1.Hainan Med Univ, Engn Res Ctr Trop Med Innovat, Sch Pharm & Transformat, Minist Educ, Haikou, Hainan, Peoples R China
2.Univ Tokyo, Sch Sci, Dept Chem, Tokyo, Japan
3.Res Ctr Deepsea Bioresources, Sanya, Hainan, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Struct & Funct Drug Targets, State Key Lab Drug Res, Shanghai, Peoples R China
5.Fudan Univ, Sch Basic Med Sci, Dept Pharmacol, Shanghai, Peoples R China
6.Univ Chinese Acad Sci, Beijing, Peoples R China
7.Chinese Acad Sci, Natl Ctr Drug Screening, Shanghai Inst Mat Med, Shanghai, Peoples R China
8.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Chem Biol, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Li, Wenzhuo,Zhou, Qingtong,Cong, Zhaotong,et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide[J]. CELL DISCOVERY,2024,10(1):4.
APA Li, Wenzhuo.,Zhou, Qingtong.,Cong, Zhaotong.,Yuan, Qingning.,Li, Wenxin.,...&Wang, Ming-Wei.(2024).Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.CELL DISCOVERY,10(1),4.
MLA Li, Wenzhuo,et al."Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide".CELL DISCOVERY 10.1(2024):4.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。